6 days Ago By ABMN Staff
XTX Topco Ltd acquired a new stake in shares of OraSure Technologies, Inc. ( NASDAQ:OSUR – Free Report ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 49,065 shares of the medical instruments supplier’s stock, valued at approximately $177,000.
A number of other hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in OraSure Technologies by 23.1% during the 4th quarter.
Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock valued at $10,016,000 after purchasing an additional 521,400 shares in the last quarter. American Century Companies Inc. grew its stake in OraSure Technologies by 11.
4% during the 4th quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after purchasing an additional 240,224 shares in the last quarter.
Geode Capital Management LLC grew its position in shares of OraSure Technologies by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 1,844,139 shares of the medical instruments supplier’s stock worth $6,659,000 after acquiring an additional 46,325 shares in the last quarter.
JPMorgan Chase & Co. grew its position in shares of OraSure Technologies by 5.8% in the 3rd quarter.
JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock worth $3,621,000 after acquiring an additional 46,216 shares in the last quarter. Finally, Archon Capital Management LLC grew its position in shares of OraSure Technologies by 145.
1% in the 4th quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock worth $2,988,000 after acquiring an additional 490,034 shares in the last quarter. Institutional investors and hedge funds own 93.
50% of the company’s stock. OraSure Technologies Trading Up 1.7 % Shares of OSUR opened at $3.
04 on Tuesday. The firm has a market cap of $235.56 million, a price-to-earnings ratio of 20.
27 and a beta of 0.76. The stock has a 50 day moving average of $3.
29 and a 200-day moving average of $3.69. OraSure Technologies, Inc.
has a 52 week low of $2.69 and a 52 week high of $5.59.
Analyst Upgrades and Downgrades Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Get Our Latest Stock Analysis on OSUR Insider Activity at OraSure Technologies In related news, Director John P.
Kenny acquired 47,659 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $3.17 per share, for a total transaction of $151,079.
03. Following the transaction, the director now directly owns 70,915 shares of the company’s stock, valued at $224,800.55.
This trade represents a 204.93 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link .
Also, CFO Kenneth J. Mcgrath acquired 64,000 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average price of $3.
15 per share, with a total value of $201,600.00. Following the transaction, the chief financial officer now directly owns 371,013 shares in the company, valued at approximately $1,168,690.
95. This trade represents a 20.85 % increase in their ownership of the stock.
The disclosure for this purchase can be found here . Insiders purchased 190,284 shares of company stock worth $600,348 in the last 90 days. 3.
90% of the stock is currently owned by company insiders. OraSure Technologies Profile ( Free Report ) OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.
E.D. Recommended Stories Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. ( NASDAQ:OSUR – Free Report ). Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.
com's FREE daily email newsletter ..
